News
ENGNW
0.1799
-14.33%
-0.0301
Weekly Report: what happened at ENGN last week (1109-1113)?
Weekly Report · 2d ago
enGene: Downgrading To 'Sell' On Non-Competitive Efficacy Detalimogene For NMIBC
Seeking Alpha · 5d ago
Leerink Partners Upgrades enGene Therapeutics to Outperform from Market Perform
NASDAQ · 5d ago
Leerink upgrades enGene to Outperform as worst-case scenario off the table
TipRanks · 5d ago
enGene Holdings (ENGN) Receives a Hold from Guggenheim
TipRanks · 5d ago
enGene Therapeutics Price Target Announced at $5.00/Share by Leerink Partners
Dow Jones · 5d ago
enGene Therapeutics Raised to Outperform From Market Perform by Leerink Partners
Dow Jones · 5d ago
Leerink Partners Upgrades enGene Therapeutics to Outperform, Announces $5 Price Target
Benzinga · 5d ago
enGene upgraded to Outperform from Market Perform at Leerink
TipRanks · 5d ago
Biotech Stocks Rally: ADXN Soars 71%, ENGN Jumps 26%, NTHI Gains 12%, PRQR Rises 10%
NASDAQ · 6d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 6d ago
enGene rises after mid-stage trial data for bladder cancer therapy; Piper upgrades
Seeking Alpha · 6d ago
This AMD Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Benzinga · 6d ago
enGene Therapeutics Raised to Overweight From Neutral by Piper Sandler
Dow Jones · 6d ago
enGene Therapeutics Price Target Maintained With a $4.00/Share by Piper Sandler
Dow Jones · 6d ago
Piper Sandler Upgrades enGene Therapeutics to Overweight, Maintains Price Target to $4
Benzinga · 6d ago
enGene Announces LEGEND Trial Results and FDA Alignment
TipRanks · 6d ago
enGene Therapeutics Price Target Raised to $6.00/Share From $2.00 by Wells Fargo
Dow Jones · 6d ago
enGene Therapeutics Raised to Overweight From Equal-Weight by Wells Fargo
Dow Jones · 6d ago
Analysts’ Top Healthcare Picks: enGene Holdings (ENGN), Janux Therapeutics Inc (JANX)
TipRanks · 6d ago
More
Webull provides a variety of real-time ENGNW stock news. You can receive the latest news about enGene Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENGNW
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.